anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a high-efficiency low-toxicity anti-cancer compound synthesized by autocatalysis in cells and living bodies. The anti-cancer compound is prepared by means of chemical synthesis of a metal complex precursor and an organic active molecule precursor outside the cells or synthesis of the metal complex precursor and the organic active molecule precursor in the cells by means of a bioorthogonal reaction. The metal complex is a platinum, ruthenium, iridium or osmium metal complex, and the organic active molecule means small organic molecules having certain biological activities, for example, the small organic molecules having biological activities such as anti-inflammation, anti-bacteria, anti-angiogenesis, and anti-cancer. The organic active molecule precursor is an organic active molecule subjected to chemical modification, and the organic active molecule is one of rhein acid, oleanolic acid, ursolic acid, naphthalimide, cumarin acid, anthracene-9-carboxylic acid or indometacin. Also disclosed is a synthesis method for the anti-cancer compound. The anti-cancer compound in the present invention shows a good anti-tumor effect by being synthesized by means of either an extracellular reaction or an intracellular reaction.
Pharmaceutical compositions suitable for use in the treatment of respiratory diseases comprising a cysteine ester in the form of a salt with a pharmaceutically acceptable acid and a bronchodilator drug are administered by inhalation from an aerosol dispenser or container delivering a metered dose, the active ingredients preferably having a particle size of less than 50 microns being dissolved in a liquid medium comprising a solubilizing co-solvent and an aerosol propellant.  The aerosol propellant may be trichloromonofluoromethane, dichloromonofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane and/or trichlorotrifluoroethane and the solubilizing co-solvent may be ethanol or propylene glycol. The compositions may also contain other medicaments, e.g. hormones, enzymes, alkaloids, steroids, analgesics, antihistamines, antibiotics or sulphonamides or synergistic combinations thereof and surface active agents e.g. ethylene glycol, glycerol, erythritol, mannitol, sorbitol and sorbitol anhydrides, particularly sorbitan mono- or tri-oleates.ALSO:A pharmaceutical composition, suitable for use in the treatment of respiratory diseases in which there is congestion of the respiratory passages with mucus, and having enhanced mucolytic properties together with bronchodilator properties, comprises (a) the salt with a pharmaceutically acceptable acid of a cysteine ester, preferably the salt of an alkyl cysteine ester having from 1 to 6 carbon atoms in the alkyl group such as the methyl or ethyl ester, and (b) a bronchodilator drug, for instance a sympathomimetic amine such as adrenaline, iso prenaline, phenyl ephrine and ephedrine in the form, if desired, of a salt with a pharmaceutically acceptable acid.  The cysteine ester is preferably a L-cysteine ester and salts may be formed with inorganic mineral acids (e.g. hydrochloride salt) and organic acids (e.g. maleate, hydrogen maleate, tartrate, hydrogen tartrate and sodium or potassium maleate or tartrate salts, and succinate and ascorbate salts).  The compositions may also contain other medicaments, e.g. hormones, enzymes, alkaloids, steroids, analgesics, antihistamines, antibiotics or sulphonamides or synergistic combinations thereof.  The compositions are administered by inhalation from an aerosol dispenser or container delivering a metered dose, the active ingredients (preferably having a particle size of less than 50 microns) being dissolved in a liquid medium comprising a solubilising co-solvent and an aerosol propellant.
Disclosed are methods and corresponding systems and devices for providing an estimation model for use with one or more instances of a particular sensor. In some aspects, an estimation model usable for estimating a value of a physiological condition is determined based at least in part on simulated measurements. The simulated measurements are generated for a first sensor, through applying a translation model to convert historical measurements associated with a second sensor into measurements that would have been produced by the first sensor. The second sensor has a different design or configuration than the first sensor. The historical measurements represent changes in the physiological condition as observed by different instances of the second sensor. The estimation model can be made available to one or more electronic devices, including at least one device configured to apply the estimation model to a measurement from a corresponding instance of the first sensor.
Described embodiments provide systems and methods for generating a corrected planar scintigraphy image (CPSI) corrected for image artifacts. A computing system can obtain a plurality of planar scintigraphy images of a subject. The plurality of planar scintigraphy images may contain image artifacts caused by one or more physical processes. The computing system may generate a CPSI corrected for the image artifacts by applying a planar scintigraphy image reconstruction model to the plurality of planar scintigraphy images. The planar scintigraphy image reconstruction model may comprise a non-negativity constraint and be based on a regularization term and a fidelity term. The computing system may present the CPSI for evaluation of a condition of the subject. Presenting the CPSI may comprise at least one of transmitting the CPSI to a computing device or displaying the CPSI on a display screen.
Study design: Open pilot study in health volunteers in the Hospital Saint-ANTOINE's Clinical Investigation Centre (CIC).

Recruitment and course of the study: The subjects will be recruited among the CIC's pool of healthy volunteers. Volunteer people will then have biological and clinical baseline examinations. If they match the inclusion criteria, an appointment will be taken for the blood sample intend for the characterization of the EPC and hormonal plasma levels evaluation. The participation will not exceed 2 months. Young women will have to come between the 9th and the 11th day after the beginning of menses). A total of 150 ml of peripheral blood will be collected. The study will last 18 months.
### Liver Function

Ticlopidine therapy has been associated with elevations of alkaline phosphatase, bilirubin, and transaminases, which generally occurred within 1 to 4 months of therapy initiation. In controlled clinical trials in stroke patients, the incidence of elevated alkaline phosphatase (greater than two times upper limit of normal) was 7.6% in ticlopidine patients, 6% in placebo patients and 2.5% in aspirin patients. The incidence of elevated AST (SGOT) (greater than two times upper limit of normal) was 3.1% in ticlopidine patients, 4% in placebo patients and 2.1% in aspirin patients. No progressive increases were observed in closely monitored clinical trials (eg, no transaminase greater than 10 times the upper limit of normal was seen), but most patients with these abnormalities had therapy discontinued. Occasionally patients had developed minor elevations in bilirubin.

Postmarketing experience includes rare individuals with elevations in their transaminases and bilirubin to >10X above the upper limits of normal. Based on postmarketing and clinical trial experience, liver function testing, including ALT, AST, and GGT, should be considered whenever liver dysfunction is suspected, particularly during the first 4 months of treatment.
A cosmetic article comprises water-insoluble substrate having one or more layers and an oil-in-water emulsion-type composition added or impregnated on substrate. The oil-in-water emulsion-type composition contains at least one thickening polymer chosen from copolymer obtained by polymerization of at least one monomer (m1) chosen from carboxylic acid-containing (alpha ),(beta )-ethylenically unsaturated compound or its ester with at least one ethylenically unsaturated monomer (m2) having hydrophobic group, and polymer comprising at least one monomer having sulfo group, and inulin. A cosmetic article comprises water-insoluble substrate having one or more layers and an oil-in-water emulsion-type composition added or impregnated on the substrate. The oil-in-water emulsion-type composition has oily phase dispersed in aqueous phase. The oil-in-water emulsion-type composition contains at least one thickening polymer chosen from copolymer obtained by polymerization of at least one monomer chosen from monomer (m1) of carboxylic acid-containing (alpha ),(beta )-ethylenically unsaturated compound or its ester with at least one ethylenically unsaturated monomer (m2) having hydrophobic group, and polymer comprising at least one monomer having sulfo group, and at least one inulin modified by hydrophobic chains. An independent claim is included for cosmetic composition, which is in the form of oil-in-water emulsion comprising oily phase dispersed in aqueous phase. The content of aqueous phase is 40 wt.% or more. The cosmetic composition further contains additional emulsifying agent (5 wt.% or less).
BACKGROUND: Sarcopenia has been identified as a potential negative prognostic factor in cancer patients. In this study, our objective was to investigate the relationship between the assessment method for sarcopenia using the masseter muscle volume measured on computed tomography (CT) images and the life expectancy of patients with oral cancer. We also developed a learning model using deep learning to automatically extract the masseter muscle volume and investigated its association with the life expectancy of oral cancer patients.
METHODS: To develop the learning model for masseter muscle volume, we used manually extracted data from CT images of 277 patients. We established the association between manually extracted masseter muscle volume and the life expectancy of oral cancer patients. Additionally, we compared the correlation between the groups of manual and automatic extraction in the masseter muscle volume learning model.
RESULTS: Our findings revealed a significant association between manually extracted masseter muscle volume on CT images and the life expectancy of patients with oral cancer. Notably, the manual and automatic extraction groups in the masseter muscle volume learning model showed a high correlation. Furthermore, the masseter muscle volume automatically extracted using the developed learning model exhibited a strong association with life expectancy.
CONCLUSIONS: The sarcopenia assessment method is useful for predicting the life expectancy of patients with oral cancer. In the future, it is crucial to validate and analyze various factors within the oral surgery field, extending beyond cancer patients.
Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
Psoriasis is a globally prevalent chronic inflammatory skin disease. This study aimed to scrutinize the hub genes related to inflammation and potential molecular mechanisms in psoriasis. Utilizing mRNA expression profiles from public datasets GSE13355, GSE78097, and GSE14905, we set up a comprehensive analysis. Initially, we selected differentially expressed genes (DEGs) from psoriasis and control samples in GSE13355, followed by calculating inflammatory indices using genomic set variation analysis (GSVA). Weighted gene co-expression network analysis (WGCNA) was then applied to link significant modules with the inflammatory index. This process helped us identify differentially expressed inflammation-related genes (DE-IRGs). A protein-protein interaction (PPI) network was established, with the molecular complex detection (MCODE) plug-in pinpointing six chemokine genes (CCR7, CCL2, CCL19, CXCL8, CXCL1, and CXCL2) as central hub genes. These genes demonstrated pronounced immunohistochemical staining in psoriatic tissues compared to normal skin. Notably, the CCR7 gene exhibited the highest potential for m6A modification sites. Furthermore, we constructed transcription factor-microRNA-mRNA networks, identifying 139 microRNAs and 52 transcription factors associated with the hub genes. For the LASSO logistic regression model, the area under the curve (AUC) in the training set was 1, and in the two validation cohorts GSE78097 and GSE14905 were 1 and 0.872, respectively. In conclusion, our study highlights six chemokine genes (CCR7, CCL2, CCL19, CXCL8, CXCL1, and CXCL2) as potential biomarkers in psoriasis, providing insights into the immune and inflammatory responses as pivotal instances in disease pathogenesis. These findings pave the way for exploring new therapeutic targets, particularly focusing on chemokine-associated pathways in psoriasis treatment.
The invention relates to preservative systems which are particularly suitable in cosmetic and dermatological preparations. The preservative system which comprises a cationic surfactant, derived from the condensation of fatty acids and esterified dibasic amino acids, having the formula (I) where: X-is Br-, C1-, or HSO 4 R1: is a straight alkyl chain from an acid or saturated fatty hydroxy acid from 8 to 14 atoms of carbon bonded to the .alpha.-amino acid group through amidic bond. R2: is a straight or branched alkyl chain from 1 to 18 carbon atoms or aromatic. R3: is: (II) where n can be from 0 to 4, is combined with at least one other ionic or non-ionic preservative agent, whereby the combination displays a synergetic activity. A preservative system, wherein the cationic surfactant preservative derived from the condensation of fatty acids and esterified dibasic amino acid is LAE is particularly preferred. The other ionic or non ionic preservative agent is preferably at least one component selected from the group consisting of 2-bromo-2-nitro-1,3-propanediol (bronopol), parbens, imidazolidinyl urea, phenoxyethanol, DMDM  hydantoin, 2-methyl-5-chloro-3,4-isothiazolinone/2-methyl-3,4-isothiazolinone and quaternium-15.
INTRODUCTION: The mucosa-associated microbiota (MAM) is not as frequently studied in diarrhea-predominant irritable bowel syndrome (IBS-D) compared with the fecal microbiota. In this study, we examined the MAM in the terminal ileum and its correlation with bowel symptoms in IBS-D.
METHODS: Mucosal biopsies of the terminal ileum from 25 patients with IBS-D and 25 healthy controls were collected for 16S ribosomal RNA gene sequencing. Correlation analysis was performed.
RESULTS: Compared with healthy controls, the MAM in the terminal ileum showed a decreased alpha diversity in the IBS-D cohort (Chao1 and Shannon indexes, P < 0.05). And the overall MAM profile clustered separately into 2 groups (ADONIS [PERMANOVA, permutational multivariate analysis of variance], P < 0.05). At the phylum level, the relative abundance of Proteobacteria was significantly higher in the ileal MAM of patients with IBS-D while that of Firmicutes was significantly lower. At the genus level, the relative abundance of Pseudomonas was significantly higher in the IBS-D cohort, with lower Bacteroides and Ruminococcus . Moreover, 40.0% of patients with IBS-D had multiple small nodules (nodular lymphoid hyperplasia) on the mucosal surface of the terminal ileum, which indicated a low-grade inflammation. In patients with IBS-D with nodular lymphoid hyperplasia, the changes of Pseudomonas and Bacteroides were more overt. Correlation analysis revealed that the relative abundance of Pseudomonas positively correlated with abdominal pain and the severity of IBS.
DISCUSSION: Patients with IBS-D showed a dysbiosis of MAM in the terminal ileum, which may be associated with bowel symptoms. Moreover, 40.0% of them displayed mucosal low-grade inflammation, with a more severe mucosal microbial disturbance.
The invention relates to a campus dispensary intelligent appointment feedback system including a student sub terminal, a dispensary terminal and a teacher terminal. The student sub terminal incldues a student identity information module, a first display module, a first communication module and a first input module. The first input module is used for inputting appointment information and inputing evaluation feedback and treatment effect feedback. The dispensary terminal incldues a student identity verification module, a second display module a second communication module and a second input module. The second input module is used for ensuring appointment information, appointmetn time and feedback infromation. When a student seeks medical advice, he or she inputs the appointment information on the first input module which then sends the information to the dispensary terminal and the teacher terminal, and then the first display module shows appointment status and feedback appointment time and hte like issues.
PURPOSE: Respiratory dysfunction is one of the most frequent symptoms observed during sepsis reflecting hypoxemia and/or acidosis that may be assessed by the ROX index (ratio of oxygen saturation by pulse oximetry/fraction of inspired oxygen to respiratory rate). This study aimed to describe the relationship between the prehospital ROX index and 30-day mortality rate among septic shock patients cared for in the prehospital setting by a mobile intensive care unit (MICU).
METHODS: From May 2016 to December 2021, 530 septic shock patients cared for by a prehospital MICU were retrospectively analysed. Initial ROX index value was calculated at the first contact with MICU. A Cox regression analysis after propensity score matching was performed to assess the relationship between 30-day mortality rate and a ROX index ≤ 10.
RESULTS: Pulmonary, digestive and urinary sepsis were suspected among 43%, 25% and 17% patients, respectively. The 30-day overall mortality reached 31%. Cox regression analysis showed a significant association between 30-day mortality and a ROX index ≤ 10: adjusted hazard ratio of 1.54 [1.08-2.31], p < 0.05.
CONCLUSIONS: During the prehospital stage of septic shock patients cared for by a MICU, ROX index is significantly associated with 30-day mortality. A prehospital ROX ≤ 10 value is associated with a 1.5-fold 30-day mortality rate increase. Prospective studies are needed to confirm the ability of prehospital ROX to predict sepsis outcome since the prehospital setting.
PURPOSE: Provided is a novel vascular embolic material comprising a mixture of hydrophilic high molecular substances and metallic substances, and in bead form or sponge form. The novel material shows a therapeutic effect on various cancers and vascular malformation, and enables to make its clinical uses easily, to help diagnosis of pre- and pro- embolic operation, and to promote the effects of radiotherapy of tumor and anti-cancer therapy. CONSTITUTION: A multi-functional vascular embolic material comprises a mixture of hydrophilic high molecular substances and metallic substances preferentially in a ratio of 4-10 to 1, in bead form or sponge form. The hydrophilic high molecular substance is preferentially polyvinylalcohol having molecular weight of 50,000-300,000. The metallic substance is preferentially selected from the group consisting of TiO2, Pt, or mixture thereof. The novel material is prepared by drying in oil method or freeze drying method.
The present study is a monocentric, between-subjects, randomized, placebo-controlled trial. The investigators will recruit approximately 40 young-adult, male individuals with a clinical diagnosis of Autism Spectrum Disorder (ASD). Participants will be randomly allocated to an experimental group (Oxytocin (OT)) and a control group (Placebo (PL)). All participants will receive the same frequency and duration of intervention. Behavioral and neural outcome measures will be assessed at multiple time points in a period of a year. Participants will be tested at 5 occasions: before and after a single dose of nasal spray, after multiple doses of nasal spray (1 daily dose of nasal spray during 4 weeks), after a 4-week retention period and after a 1-year retention period. At each time point participants will be tested at both the behavioral and neural level. Test performance of both participant groups (OT vs PL) will be compared by measuring reaction times and accuracy rates in a computerized task assessing a person's ability to recognize bodily emotional states from point light displays. In addition, attachment, social functioning, restricted behaviour, general quality of life and mood will be assessed via self-reported questionnaires.

Functional MRI measurements will be performed in a 3T MR Philips Intera scanner. Before scanning, subjects will undergo a training session to familiarize them with the task instructions. In addition to the fMRI measurements, resting state fMRI and Diffusion Tensor Imaging (DTI) will also be performed to reveal alterations of the functional and structural connectivity between critical regions.

Statistical analysis of the behavioral data will have a between-subject factor of group (OT vs PL) and within-subject factors of time (change-from-baseline). Image analysis will be performed with Statistical Parametric Mapping (SPM) software. The investigators will contrast for either decreased or increased activation, as different regions may show divergent changes due to the received nasal spray (either OT or PL).
An inhaler type medicine administering device comprises a generally cylindrical inhaling piece including a holder accommodating section located at one side of the inhaling piece, and an inhaling mouth located at the other side of the inhaling piece. A generally cylindrical capsule holder is disposed in the holder accommodating section and formed with a capsule accommodating hole which opens at one end of the capsule holder. A capsule is to be disposed in the capsule accommodating hole. First and second pin insertion holes are formed in the capsule holder and the inhaling piece and respectively located to be connected with axially opposite sections of the capsule accommodating hole. Each pin insertion hole extends generally in a diametrical direction of the inhaling piece and the capsule holder. An air flow passage is axially formed at at least one of an inner peripheral surface of the inhaling piece and an outer peripheral surface of the capsule holder. The first and second pin insertion holes are communicated with each other through the air flow passage. Additionally, a perforator is provided having first and second pins which are to be inserted respectively into the first and second pin insertion holes to form holes in the capsule which holes are in communication with the air flow passage.